FINWIRES · TerminalLIVE
FINWIRES

欧洲、中东和非洲地区石油市场最新动态:随着中东冲突加剧,期货价格从历史高位回落

By

-- 周四,原油期货价格回落,布伦特原油期货早盘一度突破每桶126美元大关,原因是交易员们担心美伊战争将导致长期供应短缺。 近月穆尔班原油期货下跌3.4%,至每桶109.61美元;布伦特原油期货下跌3.3%,至每桶114.11美元,早盘一度触及每桶126美元的高点。 澳新银行分析师表示:“随着供应短缺加剧,布伦特原油价格跌破每桶120美元。” 澳新银行补充道:“由于霍尔木兹海峡无限期关闭的前景令市场情绪承压,原油价格的上涨势头没有放缓的迹象。” 外交关系的破裂,加上特朗普总统指示做好长期封锁的准备,使得交易员们担心长期供应短缺,而仅靠需求下降可能无法弥补这一缺口。 “美伊谈判破裂,加上据报道特朗普总统拒绝了伊朗关于重新开放霍尔木兹海峡的提议,令市场对石油供应迅速恢复失去希望,”荷兰国际集团(ING)表示。 “尽管我们估计需求下降幅度约为160万桶/日,这固然可观,但显然不足以弥补我们目前面临的供应缺口,”荷兰国际集团补充道。 市场依赖现有库存的能力正在迅速下降。 分析公司Kpler的数据显示,伊朗仅剩下12至22天的未使用储存能力。 一旦这些设施满负荷运转,德黑兰将被迫额外削减每日150万至160万桶的产量。 此次即将到来的减产将叠加在因海峡关闭而已停产的约1000万桶/日的产量之上。 荷兰国际集团(ING)分析师警告称,尽管区域需求下降幅度估计约为160万桶/日,但仍不足以弥补不断扩大的供应缺口,这意味着大幅提价可能是平衡市场的唯一手段。 美国能源信息署(EIA)周三发布的周报显示,截至4月24日当周,美国原油库存下降620万桶至4.595亿桶,供应趋紧的迹象显现。 与此同时,据报道,特朗普周三表示,阿联酋退出欧佩克的决定可能有助于缓解能源价格上涨。

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Firstenergy Corp.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target by $1 to $55, 20.0x our next-12-month EPS view of $2.75, a premium to its five-year average of 15.6x. We reduce our 2026 EPS view by $0.02 to $2.72 and 2027 EPS by $0.01 to $2.93. The Q1 core EPS increase (+7.5% Y/Y) breaks a three-quarter streak of declines, and we see continued momentum throughout our forecast horizon. We see positive data center demand trends, with long-term contracted demand (4.3 GW) up 4% since February 2026 (4.1 GW) and up 47% since February 2025 (2.9 GW), while pipeline demand (14.9 GW) is up 15% since February 2026 (12.9 GW) and has more than doubled since February 2025 (6.1 GW). FE has reduced base O&M by over $200M (15%) since 2022, with Q1 2026 showing an additional ~5% YoY decline, while simultaneously improving reliability metrics. We think FE's cost discipline, service quality improvement, and competitive rate positioning should translate into more favorable rate case outcomes, reduced disallowance risk, and potentially higher allowed ROEs.

$FE
Sectors

Sector Update: Consumer

Consumer stocks were higher Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 1.4% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increasing 0.4%.In corporate news, Lamb Weston (LW) shares rose 1.6% after shareholder Starboard Value said in a letter to the board Thursday that the company should hold an investor day and reset earnings to a normalized level.

$LW
Australia

Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug

The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%

$AZN